Negative in Ames, in vitro chromosome aberration and rat bone marrow micronucleus assays
“Ibrexafungerp was negative for genotoxicity in both nonclinical in vitro assays (Ames assays and a chromosome aberration assay in mammalian cells) and in vivo studies (micronucleus study in rat bone marrow cells).”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Carcinogenicity
Not conducted (limited duration of use for VVC)
“Carcinogenicity studies were not performed for ibrexafungerp due to the limited duration of its intended use for the treatment of VVC.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rabbit EFD: limb, ear and body-wall malformations at about 5x human exposure
“In pregnant rabbits, oral ibrexafungerp administered during organogenesis was associated with fetal malformations including absent forelimb(s), absent hindpaw, absent ear pinna, and thoracogastroschisis at dose exposures greater or equal to approximately 5 times the human exposure at the RHD.”
“Results from an in vitro hERG assay indicated that the ibrexafungerp IC50 for hERG inhibition was 1.4-fold higher than the plasma Cmax value associated with the recommended clinical dose of 600 mg/day ibrexafungerp in fed patients.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Genotox: Ames
Negative (Ames)
“Ibrexafungerp was negative for genotoxicity in both nonclinical in vitro assays (Ames assays and a chromosome aberration assay in mammalian cells) and in vivo studies (micronucleus study in rat bone marrow cells).”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Genotox: in vitro mammalian
Chromosome aberration assay in mammalian cells: negative
“Ibrexafungerp was negative for genotoxicity in both nonclinical in vitro assays (Ames assays and a chromosome aberration assay in mammalian cells) and in vivo studies (micronucleus study in rat bone marrow cells).”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Genotox: in vivo
Rat bone marrow micronucleus: negative
“Ibrexafungerp was negative for genotoxicity in both nonclinical in vitro assays (Ames assays and a chromosome aberration assay in mammalian cells) and in vivo studies (micronucleus study in rat bone marrow cells).”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Carcinogenicity model
Not conducted (limited duration of use for VVC)
“Carcinogenicity studies were not performed for ibrexafungerp due to the limited duration of its intended use for the treatment of VVC.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Carcinogenicity timing
Not performed due to the limited duration of use for VVC
“Carcinogenicity studies were not performed for ibrexafungerp due to the limited duration of its intended use for the treatment of VVC.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
hERG / QT
hERG IC50 only ~1.4-fold above clinical Cmax at 600 mg/day
“Results from an in vitro hERG assay indicated that the ibrexafungerp IC50 for hERG inhibition was 1.4-fold higher than the plasma Cmax value associated with the recommended clinical dose of 600 mg/day ibrexafungerp in fed patients.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative